Close

Lenti-OVA TCR-VP (VP-TCR-C361)

The ready-to-use lentiviral particles of Lenti-OVA TCR-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of Human TCR will be driven by a CMV promotor. The target gene of TCR packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.

Specifications

  • Type of Therapeutics
  • T cell receptor
  • Target
  • OVA
  • Promotor
  • CMV
  • Packaging System
  • Lentivirus
  • Packaging Cell
  • 293T
  • Targeting Diseases
  • Food allergy

Target

  • Introduction
  • This peptide is amino acids 323 to 339 amidated fragment of ovalbumin (OVA), the H-2b-restricted
    OVA class II epitope. This peptide is recognized by many T cells because it contains multiple T cell
    epitopes. This OVA fragment contains a nested set of CD4+ T cell epitopes. OVA 323 to 339 can be
    presented by I-Ad in at least three binding registers. The residues 327 to 333 are critical for peptide
    binding to I-Ad
  • Alternative Names
  • Tra-P1A; Trap1a; tumor rejection antigen P1A; TCR; T cell receptor; transgenic TCR; antigen-specific T cell receptors; Engineering T-cell receptors; recombinant t cell receptors; specific t cell receptor; modified t cell receptor; retroviral vector; Spleen cancer; thymus cancer; liver cancer; lung cancer

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry
Products

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.